Kidney injury induced by deferasirox dispersible tablets
10.3760/cma.j.cn114015-20191111-00901
- VernacularTitle:地拉罗司分散片致肾损伤
- Author:
Sisi JIN
1
;
Jinsheng JIA
1
Author Information
1. 晋城大医院药学部，山西省晋城市 048006
- Publication Type:Journal Article
- Keywords:
Iron metabolism disorders;
Deferasirox;
Kidney injury
- From:
Adverse Drug Reactions Journal
2020;22(9):541-542
- CountryChina
- Language:Chinese
-
Abstract:
A 73-year-old male patient with myelodysplastic syndrome received deferasirox dispersible tablets (deferasirox) 500 mg once daily for post-transfusion iron overload. Renal function examination showed no obvious abnormality. Ten months later, the dose of deferasirox was increased to 1 000 mg once daily due to ineffective iron overload treatment. About 1 month after the dose adjustment, the patient′s fatigue was aggravated. Laboratory tests showed blood urea (BUN) 11.5 mmol/L, serum creatinine (Scr) 143 μmol/L, and estimated glomerular filtration rate (eGFR) 45 ml/(min·1.73 m 2). Kidney injury was diagnosed, which was considered to be induced by deferasirox. Then deferasirox was stopped and Corbrin capsule (百令胶囊) was given. About 1 month after drug withdrawal, renal function of the patient was improved [BUN 9.1 mmol/L, Scr 111 μmol/L, and eGFR 60 ml/(min·1.73 m 2)]. Due to the iron overload, deferasirox was re-given at dose of 1 000 mg once daily. About 1 month after medication, the kidney injury recurred [BUN 9.7 mmol/L, Scr 131 μmol/L, and eGFR 49 ml/(min·1.73 m 2)]. The dose of deferasirox was reduced to 500 mg once daily immediately and 3 month later, renal function of the patient was improved [BUN 8.8 mmol/L, Scr 104 μmol/L, and eGFR 65 ml/(min·1.73 m 2)].
